– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients.
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 11,900,000 shares, an increase of 12.9% from the April 30th total of 10,540,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio […]
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 11,900,000 shares, a growth of 12.9% from the April 30th total of 10,540,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the days-to-cover ratio […]
Coherus BioSciences (NASDAQ:CHRS – Get Rating) had its target price lowered by Barclays from $13.00 to $8.00 in a research note issued to investors on Tuesday, The Fly reports. A number of other equities research analysts have also issued reports on CHRS. StockNews.com started coverage on Coherus BioSciences in a research note on Thursday, May […]